Payment overview · 2025
General Payments
$162.32
8 reported records · 3 companies
Healthcare provider profile · identity verified
Ramiro Coro, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HIALEAH, FL · NPI 1851320790
Verified facts
What the public records show
CMS Open Payments records show Ramiro Coro, M.D. received $162.32 in general payments during 2025 across 8 reported records.
Amgen Inc. accounted for 47.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGLYZA as an associated drug or biological on 111 records involving 89 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Onglyza by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $76.33 | 47.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.55 | 31.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $35.44 | 21.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $162.32 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $76.33 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.55 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.32 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $35.44 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | ONGLYZA open payments reported associated product |
CMS Open Payments — General Payments 111 supporting records · 89 recipient NPIs · example record 1206133840 |
Onglyza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 434 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 95 |
| Clonazepam | Clonazepam | 289 | 44 |
| Losartan Potassium | Losartan Potassium | 275 | 73 |
| Metformin Hcl | Metformin Hcl | 236 | 59 |
| Gabapentin | Gabapentin | 225 | 55 |
| Omeprazole | Omeprazole | 207 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 201 | 61 |
| Alprazolam | Alprazolam | 193 | 28 |
| Famotidine | Famotidine | 179 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 166 | 35 |
| Jardiance | Empagliflozin | 159 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 145 | 36 |
| Furosemide | Furosemide | 133 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 126 | 36 |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 124 | 29 |
| Ibuprofen | Ibuprofen | 121 | 30 |
| Meloxicam | Meloxicam | 121 | 21 |
| Montelukast Sodium | Montelukast Sodium | 118 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 27 |
| Lisinopril | Lisinopril | 115 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 24 |
| Mounjaro | Tirzepatide | 112 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 31 |
| Ezetimibe | Ezetimibe | 102 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 26 |
| Nifedipine Er | Nifedipine | 93 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 92 | 29 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 91 | 25 |
| Eliquis | Apixaban | 89 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 22 |
| Allopurinol | Allopurinol | 87 | 21 |
| Ammonium Lactate | Ammonium Lactate | 83 | 17 |
| Simvastatin | Simvastatin | 76 | 20 |
| Glipizide Er | Glipizide | 75 | 24 |
| Linzess | Linaclotide | 75 | 22 |
| Glimepiride | Glimepiride | 72 | 15 |
| Synthroid | Levothyroxine Sodium | 72 | 17 |
| Azithromycin | Azithromycin | 70 | 53 |
| Carvedilol | Carvedilol | 67 | 14 |
| Mupirocin | Mupirocin | 66 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 16 |
| Ketoconazole | Ketoconazole | 65 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 16 |
| Nystatin | Nystatin | 63 | 21 |
| Hydrocortisone | Hydrocortisone | 62 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 13 |
| Spironolactone | Spironolactone | 58 | 13 |
| Azelastine Hcl | Azelastine Hcl | 56 | 13 |
| Atenolol | Atenolol | 55 | 12 |
| Valsartan | Valsartan | 55 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 13 |
| Temazepam | Temazepam | 51 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 49 | suppressed |
| Memantine Hcl | Memantine Hcl | 48 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 11 |
| Ozempic | Semaglutide | 44 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | 15 |
| Sertraline Hcl | Sertraline Hcl | 43 | 12 |
| Januvia | Sitagliptin Phosphate | 41 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 40 | 34 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 39 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 38 | 11 |
| Ssd | Silver Sulfadiazine | 38 | 11 |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 14 |
| Baclofen | Baclofen | 35 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Prednisone | Prednisone | 34 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | 13 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 31 | suppressed |
| Glipizide | Glipizide | 31 | 11 |
| Procto-Med Hc | Hydrocortisone | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | 11 |
| Diclofenac Sodium Er | Diclofenac Sodium | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 13 |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 12 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 15 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Onglyza | Saxagliptin Hcl | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $162.32 · 8 records | Amgen Inc. | AIRSUPRA, OTEZLA, REPATHA, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error